Classical Hodgkin's lymphoma presenting with tongue involvement: a case report and review of the literature.

We report an unusual case of mixed cellularity classical Hodgkin's lymphoma with prominent involvement of the base of the tongue at diagnosis. In situ hybridization findings for Epstein-Barr virus were positive. Waldeyer's ring involvement by Hodgkin's lymphoma is uncommon with < 200 cases reported in the English literature and only 5 previous reports of Hodgkin's lymphoma involving the tongue.

Chemotherapy dosing in the setting of liver dysfunction.

Advanced cancer in the setting of liver dysfunction poses a dilemma for physicians, as many cancer chemotherapeutic agents undergo hepatic metabolism. Most cytotoxic drugs have a narrow therapeutic index, and the administration of chemotherapy to patients with liver impairment results in complicated safety issues. We present a concise review of cancer chemotherapy dosing in the setting of liver dysfunction.

Denileukin diftitox: a concise clinical review.

Denileukin diftitox (DAB389IL-2; Ontak) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

A review of recent findings involving interleukin-2-based cancer therapy.

Purpose Of Review: Highlighted in this review are the important preclinical and clinical updates of interleukin (IL)-2-based cancer immunotherapy that have been published during the last year.

Recent Findings: The review starts with a summary of the preclinical breakthroughs involving IL-2. The authors briefly examine two recent studies that take very different approaches to overcome the toxicities associated with IL-2 therapy.